The Latest Analyst Ratings for Alnylam Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Alnylam Pharmaceuticals (NASDAQ:ALNY) has received various analyst ratings in the last quarter, with 5 bullish, 3 somewhat bullish, and 6 indifferent. The average 12-month price target for the company is $255.79, a 6.3% decrease from the previous average of $273.00.
August 16, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and a decreased price target could lead to uncertainty among investors, potentially impacting Alnylam Pharmaceuticals' stock price.
Analyst ratings can influence investor sentiment. The mixed ratings and decreased price target for Alnylam Pharmaceuticals may lead to uncertainty, which could potentially affect the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100